Evidence mapPaperPMID 25870124Full record

Trial reportHigh blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension2015

Effects of a new combination of nutraceuticals with Morus alba on lipid profile, insulin sensitivity and endotelial function in dyslipidemic subjects. A cross-over, randomized, double-blind trial.

Valentina Trimarco, Raffaele Izzo, Eugenio Stabile, Francesco Rozza, Mario Santoro, Maria Virginia Manzi, Federica Serino, Gabriele Giacomo Schiattarella, Giovanni Esposito, Bruno Trimarco

2 registry-linked trialsOpen access · hybridAbstract readComparative StudyRandomized Controlled Trial
In one paragraph

Trial report in High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 24 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 3 pooled it
3.6field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02898805 nacompletednot on this mapstarted 2016, after this paper: background citation

Effects of a New Combination of Nutraceutics (LopiGLIK®) on Cardiovascular Risk

TypeinterventionalSponsorFederico II UniversityRan2016 to 2018Enrolled600ConditionsCardiovascular Risk FactorsArmsPlacebo, Prescribed Diet, LopiGLIK®, Armolipid Plus
NCT02969070 nacompletednot on this mapstarted 2016, after this paper: background citation

Randomized Trial to Evaluate the Effects of Two Different Nutraceutical Therapies on Endothelial Function, Platelet Aggregation, and Coronary Flow Reserve in Hypercholesterolemic Patients at Moderate Cardiovascular Risk

TypeinterventionalSponsorFederico II UniversityRan2016 to 2017Enrolled28ConditionsHypercholesterolemia, Endothelial DysfunctionArmsLopiGLIK™ therapy, Armolipid Plus® therapy
3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 3 syntheses or guidelines pooled it, 42 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Review
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Valentina TrimarcoDepartment of Neurosciences, Federico II University, Naples, Italy.
Raffaele Izzo
Eugenio Stabile
Francesco Rozza
Mario Santoro
Maria Virginia Manzi
Federica Serino
Gabriele Giacomo Schiattarella
Giovanni Esposito
Bruno Trimarco
Federico II University Hospital · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionNutraceuticals (NUT) are forms of compounds with biological activity commonly used to improve health in dosage largely exceeding those obtainable in food.

aimWe compared, in a double blind randomized cross-over trial, the effects of two NUT combinations on the control of glico-lipidic metabolism in patients with hypercholesterolemia not on statins.

methodsAt study start patients were given dietary counseling and received placebo for 2 weeks. After this run-in period, patients were randomized: (1) Combination A [Policosanol, Red yeast rice (Monakolin K 3 mg), Berberine 500 mg, Astaxantine, Folic Acid and Coenzyme Q10] for 4 weeks followed by 4 weeks of Combination B [Red yeast rice (Monakolin K 3.3 mg), Berberine 531.25 mg and leaf extract of Morus alba]; (2) Combination B for 4 weeks followed by 4 weeks of Combination A.

resultsCombination B reduced LDL cholesterol below 130 mg/dl in 56.5 % of the patients, and Cambination A only in 21.7 % of them (p ≤ 0.027). Both treatments reduced plasma levels of triglycerides, total and LDL cholesterol and increased HDL cholesterol (all p < 0.03). Total and LDL cholesterol reduction was more pronounced in patients taking Combination B (p < 0.005). Combination B reduced also glycated hemoglobin, fasting glucose and insulin plasma levels as well as HOMA index (p < 0.005).

conclusionsAn increased content of Berberin and Monacolin K and the addition of Morus alba extract improves the effect on plasma cholesterol and on glucose metabolism of the NUT Combination. These effects may allow the speculation of a more marked improvement in cardiovascular prognosis.

Indexed as

Dietary SupplementsInsulin ResistanceMorusAgedBerberineBiomarkersBlood GlucoseCross-Over StudiesDouble-Blind MethodDyslipidemiasEndothelium, VascularFemaleGlycated HemoglobinHumansHydroxymethylglutaryl-CoA Reductase InhibitorsHypolipidemic AgentsBerberineBiomarkersBlood GlucoseGlycated Hemoglobinhemoglobin A1c protein, humanHydroxymethylglutaryl-CoA Reductase InhibitorsHypolipidemic AgentsInsulinLipidsLovastatinPlant Extracts

Identifiers

PMID25870124
PMCPMC4461797
OpenAlexW2066358452

What Socratic holds

Texttitle and abstract
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.